Intravenous immunoglobulin for the treatment of Kawasaki disease

Author:

Broderick Cathryn1,Kobayashi Shinobu2,Suto Maiko3,Ito Shuichi4,Kobayashi Tohru5

Affiliation:

1. Usher Institute; University of Edinburgh; Edinburgh UK

2. Department of Social Medicine; National Center for Child Health and Development; Tokyo Japan

3. Department of Health Policy; National Center for Child Health and Development; Tokyo Japan

4. Department of Pediatrics; Graduate School of Medicine, Yokohama City University; Yokohama Japan

5. Department of Development Strategy; National Center for Child Health and Development; Tokyo Japan

Publisher

Wiley

Subject

Pharmacology (medical)

Reference158 articles.

1. Treatment of Kawaski syndrome: a comparison of two dosage regimens of intravenously administered immune globulin;Barron;Journal of Pediatrics,1990

2. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease;Burns;Journal of Pediatrics,2008

3. Infliximab (Remicade) for patients with acute Kawasaki disease clinicaltrials.gov/show/NCT00271570

4. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial;Burns;Lancet Child and Adolescent Health,2021

5. KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) clinicaltrials.gov/show/NCT03065244

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3